A phase i pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours

British Journal of Cancer

Volumn 110, Issue 9, 2014, Pages 2170-2177

  Eskens, F A L M ^a   Tresca, P ^b   Tosi, D ^b   Van Doorn, L ^a   Fontaine, H ^c   Van Der Gaast, A ^a   Veyrat Follet, C ^c   Oprea, C ^c   Hospitel, M ^c   Dieras, V ^b  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b INSTITUT CURIE   (France)

^c SANOFI   (France)

Author keywords

docetaxel; ombrabulin; pharmacokinetics; vascular disrupting agent

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; DOCETAXEL; DRUG METABOLITE; GRANULOCYTE COLONY STIMULATING FACTOR; OMBRABULIN; RPR 258063; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; AGEUSIA; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; ATRIOVENTRICULAR BLOCK; BREAST CANCER; DECREASED APPETITE; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM FISTULA; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; EPIPHORA; ERYTHEMA; ESOPHAGUS CARCINOMA; ESOPHAGUS FISTULA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEADACHE; HEMATOMA; HOT FLUSH; HUMAN; HYPERTRANSAMINASEMIA; HYPOTENSION; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; OVARY CANCER; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; PROSTATE CANCER; PRURITUS; RECOMMENDED DRUG DOSE; RESPIRATORY FAILURE; SENSORY NEUROPATHY; SEPSIS; SINUS ARRHYTHMIA; SINUS TACHYCARDIA; SKIN MANIFESTATION; SOLID TUMOR; STEADY STATE; STOMATITIS; SUPRAVENTRICULAR TACHYCARDIA; THROMBOCYTOPENIA; THROMBOSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VOMITING;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; SERINE; TAXOIDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84899956978     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.137     Document Type: Article

References (24)

1. Bonneterre J, Roche H, Monnier A, Guastalla JP, Namer M, Fargeot P, Assadourian S (2002) Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 87: 1210-1215.
2. Bonneterre J, Spielman M, Guastalla JP, Marty M, Viens P, Chollet P, Roche H, Fumoleau P, Mauriac L, Bourgeois H, Namer M, Bergerat JP, Misset JL, Trandafir L, Mahjoubi M (1999) Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience. Eur J Cancer 35: 1431-1439.
3. Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB (1998) Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16: 187-196.
4. Bruno R, Vivier N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB (1996) A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm 24: 153-172.
5. Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, Gonzalez Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A, Crown J (1999) Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17: 2341-2354.
6. Del Conte G, Bahleda R, Moreno V, Damian S, Perotti A, Lassau N, Farace F, Ong M, Stimpson S, Tunariu T, Micallef S, Demers B, Oprea C, Capri G, Soria J, Sessa C, Molife R (2012) A phase I study of ombrabulin (O) combined with bevacizumab (B) in patients with advanced solid tumors (NCT01193595) [Abstract]. J Clin Oncol 30(Suppl): Abstr No. 3080.
7. Extra JM, Rousseau F, Bruno R, Clavel M, Le Bail N, Marty M (1993) Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 53: 1037-1042.
8. Harvey V, Mouridsen H, Semiglazov V, Jakobsen E, Voznyi E, Robinson BA, Groult V, Murawsky M, Cold S (2006) Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 24: 4963-4970.
9. Hori K, Saito S (2003) Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis. Br J Cancer 89: 1334-1344.
10. Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba WJ, Pritchard KI, Mennel R, Richards D, Olsen S, Meyers ML, Ravdin PM (2005) Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23: 5542-5551.
11. Kanthou C, Tozer GM (2002) The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 99: 2060-2069.
12. Kim TJ, Ravoori M, Landen CN, Kamat AA, Han LY, Lu C, Lin YG, Merritt WM, Jennings N, Spannuth WA, Langley R, Gershenson DM, Coleman RL, Kundra V, Sood AK (2007) Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res 67: 9337-9345.
13. Lejeune P, Vrignaud P, Goulaouic H, Nicolas S, Bissery M-C (2005) In vivo synergy between docetaxel and AVE8062A, a tumor vasculature targeting agent [Abstract]. Proc AACR Annual Meeting 46: Abstr No. 3425.
14. McKeage MJ, Baguley BC (2010) Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. Cancer 116: 1859-1871.
15. Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JW, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PS, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M, Aapro M et al. (1999) Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 17: 1413-1424.
16. Nathan P, Zweifel M, Padhani AR, Koh DM, Ng M, Collins DJ, Harris A, Carden C, Smythe J, Fisher N, Taylor NJ, Stirling JJ, Lu SP, Leach MO, Rustin GJ, Judson I (2012) Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. Clin Cancer Res 18: 3428-3439.
17. Pruijn FB, van Daalen M, Holford NH, Wilson WR (1997) Mechanisms of enhancement of the antitumour activity of melphalan by the tumourblood- flow inhibitor 5, 6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 39: 541-546.
18. Sessa C, Lorusso P, Tolcher A, Farace F, Lassau N, del Monte A, Braghetti A, Bahleda R, Cohen P, Hospitel M, Veyrat-Follet C, Soria JC (2013) Phase 1 safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors. Clin Cancer Res 19: 4832-4842.
19. Siim BG, Lee AE, Shalal-Zwain S, Pruijn FB, McKeage MJ, Wilson WR (2003) Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5, 6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 51: 43-52.
20. Sjostrom J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lonn S, Bengtsson NO, Ostenstad B, Mjaaland I, Palm-Sjovall M, Wist E, Valvere V, Anderson H, Bergh J (1999) Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 35: 1194-1201.
21. Soria J, Sessa C, Perotti A, Massard C, JP A, Lassau N, Farace F, Elsa B, Gianni L (2008) A comprehensive study of translational research and safety exploration of the vascular disrupting agent (VDA) AVE8062 in combination with cisplatin administered every 3 weeks to patients with advanced solid tumors [Abstract]. Proc AACR Annual Meeting 49: Abstr LB-302.
22. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
23. Tozer GM, Kanthou C, Baguley BC (2005) Disrupting tumour blood vessels. Nat Rev Cancer 5: 423-435.
24. von Pawel J, Gorbomunova V, Reck M, Kowalski D, Allard A, Chadjaa M, Rey A, Bennouna J, Grossi F (2012) DISRUPT: a randomized phase 2 trial of ombrabulin (AVE8062) combined with a taxane-platinum regimen in the first-line treatment of metastatic non-small cell lung cancer (NSCLC) [Abstract]. Ann Oncol 23 (SupplAbs. 1250P.